Real‐life use of letermovir prophylaxis for cytomegalovirus in heart transplant recipients

Documenti analoghi

• The impact of active cytomegalovirus infection on donor‐derived cell‐free DNA testing in heart transplant recipients
  di: Amit H. Alam, et al.
  Pubblicazione: (2024)
• Postoperative cognitive dysfunction in heart transplantation recipients
  di: Qian Qin, et al.
  Pubblicazione: (2024)
• Prevalence of iron deficiency and anemia in pediatric heart transplant recipients
  di: David M. Newland, et al.
  Pubblicazione: (2024)
• Which allogeneic hematopoietic cell transplant recipients have an increased risk for delayed‐onset clinically significant cytomegalovirus infection after letermovir prophylaxis?
  di: Maria Alejandra Mendoza, et al.
  Pubblicazione: (2024)
• Cardiac allograft vasculopathy in heart transplant recipients from hepatitis C viremic donors
  di: Bernard S. Kadosh, et al.
  Pubblicazione: (2024)